Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients

Abstract Background Metastatic castration-resistant prostate cancer is the most dangerous stage of prostate cancer, with a high mortality rate. Docetaxel chemotherapy is one of the most effective treatment methods currently, but some patients do not respond to chemotherapy. To avoid unnecessary toxi...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuai Yuan, Xing Bi, Furhati Shayiti, Yue Niu, Peng Chen
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Urology
Subjects:
Online Access:https://doi.org/10.1186/s12894-024-01666-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850254060252299264
author Shuai Yuan
Xing Bi
Furhati Shayiti
Yue Niu
Peng Chen
author_facet Shuai Yuan
Xing Bi
Furhati Shayiti
Yue Niu
Peng Chen
author_sort Shuai Yuan
collection DOAJ
description Abstract Background Metastatic castration-resistant prostate cancer is the most dangerous stage of prostate cancer, with a high mortality rate. Docetaxel chemotherapy is one of the most effective treatment methods currently, but some patients do not respond to chemotherapy. To avoid unnecessary toxicity in non-responders, this study explores the potential of circulating microRNAs as early biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. Methods PC3 cells and DU145 cells were divided into the control, NC mimics, and miRNA-136-5p-mimics groups. Cell viability was measured using the CCK-8 assay. Cell apoptosis was determined by flow cytometry. Cell migration and invasion abilities were evaluated using the Transwell assay. Real-time quantitative PCR was used to measure the miRNA levels in cells and peripheral blood of patients. The miRNA-136-5p target genes were predicted by using the PITA, TargetScan, and miRanda databases. The target genes were analyzed with KEGG pathway analysis. Results In both PC3 and DU145 cells, the miRNA-136-5p-mimics group exhibited significantly increased cell survival rates, migration and invasion numbers, and significantly decreased apoptosis rates than the control group (p < 0.05). The miRNA-222-3p and miRNA-136-5p levels were significantly increased in docetaxel-resistant PC3 and DU145 cells (p < 0.05). The levels of circulating miRNA-222-3p and miRNA-136-5p were significantly associated with docetaxel treatment (p < 0.05). Higher levels of miRNA-222-3p were observed in non-responsive patients (p < 0.05). The area under the curve for miRNA-222-3p was 0.76 (95%CI: 0.55–0.97), indicating its effectiveness as a predictive factor for non-responsive patients to docetaxel. Patients with high expression of miRNA-34c-5p after docetaxel chemotherapy had shorter overall survival times (P < 0.05). Bioinformatics analysis identified 110 potential target genes of miRNA-136-5p. KEGG revealed that these genes were mainly distributed in three pathways. Among them, the PI3K-AKT pathway was closely related to the metastasis of prostate cancer cells. Conclusion Our study demonstrates that miRNA-136-5p promotes the proliferation and invasion of PC3 and DU145 cells while inhibiting apoptosis. Circulating miRNA-222-3p may serve as a biomarker for early therapeutic response to docetaxel, and further clinical investigation is warranted. Additionally, miRNA-136-5p may have anti-cancer effects during docetaxel chemotherapy in metastatic castration-resistant prostate cancer.
format Article
id doaj-art-84c54f45060c455dba99efd2e3fa7838
institution OA Journals
issn 1471-2490
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series BMC Urology
spelling doaj-art-84c54f45060c455dba99efd2e3fa78382025-08-20T01:57:13ZengBMCBMC Urology1471-24902024-12-0124111310.1186/s12894-024-01666-7Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patientsShuai Yuan0Xing Bi1Furhati Shayiti2Yue Niu3Peng Chen4Department of Urology, Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartment of Urology, Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartment of Urology, Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartment of Urology, Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartment of Urology, Affiliated Cancer Hospital of Xinjiang Medical UniversityAbstract Background Metastatic castration-resistant prostate cancer is the most dangerous stage of prostate cancer, with a high mortality rate. Docetaxel chemotherapy is one of the most effective treatment methods currently, but some patients do not respond to chemotherapy. To avoid unnecessary toxicity in non-responders, this study explores the potential of circulating microRNAs as early biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. Methods PC3 cells and DU145 cells were divided into the control, NC mimics, and miRNA-136-5p-mimics groups. Cell viability was measured using the CCK-8 assay. Cell apoptosis was determined by flow cytometry. Cell migration and invasion abilities were evaluated using the Transwell assay. Real-time quantitative PCR was used to measure the miRNA levels in cells and peripheral blood of patients. The miRNA-136-5p target genes were predicted by using the PITA, TargetScan, and miRanda databases. The target genes were analyzed with KEGG pathway analysis. Results In both PC3 and DU145 cells, the miRNA-136-5p-mimics group exhibited significantly increased cell survival rates, migration and invasion numbers, and significantly decreased apoptosis rates than the control group (p < 0.05). The miRNA-222-3p and miRNA-136-5p levels were significantly increased in docetaxel-resistant PC3 and DU145 cells (p < 0.05). The levels of circulating miRNA-222-3p and miRNA-136-5p were significantly associated with docetaxel treatment (p < 0.05). Higher levels of miRNA-222-3p were observed in non-responsive patients (p < 0.05). The area under the curve for miRNA-222-3p was 0.76 (95%CI: 0.55–0.97), indicating its effectiveness as a predictive factor for non-responsive patients to docetaxel. Patients with high expression of miRNA-34c-5p after docetaxel chemotherapy had shorter overall survival times (P < 0.05). Bioinformatics analysis identified 110 potential target genes of miRNA-136-5p. KEGG revealed that these genes were mainly distributed in three pathways. Among them, the PI3K-AKT pathway was closely related to the metastasis of prostate cancer cells. Conclusion Our study demonstrates that miRNA-136-5p promotes the proliferation and invasion of PC3 and DU145 cells while inhibiting apoptosis. Circulating miRNA-222-3p may serve as a biomarker for early therapeutic response to docetaxel, and further clinical investigation is warranted. Additionally, miRNA-136-5p may have anti-cancer effects during docetaxel chemotherapy in metastatic castration-resistant prostate cancer.https://doi.org/10.1186/s12894-024-01666-7PC3 cellsDU145 cellsDocetaxel-resistant PC3 and DU145 cellsProliferationApoptosisMigration
spellingShingle Shuai Yuan
Xing Bi
Furhati Shayiti
Yue Niu
Peng Chen
Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
BMC Urology
PC3 cells
DU145 cells
Docetaxel-resistant PC3 and DU145 cells
Proliferation
Apoptosis
Migration
title Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
title_full Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
title_fullStr Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
title_full_unstemmed Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
title_short Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
title_sort relationship between circulating mirna 222 3p and mirna 136 5p and the efficacy of docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
topic PC3 cells
DU145 cells
Docetaxel-resistant PC3 and DU145 cells
Proliferation
Apoptosis
Migration
url https://doi.org/10.1186/s12894-024-01666-7
work_keys_str_mv AT shuaiyuan relationshipbetweencirculatingmirna2223pandmirna1365pandtheefficacyofdocetaxelchemotherapyinmetastaticcastrationresistantprostatecancerpatients
AT xingbi relationshipbetweencirculatingmirna2223pandmirna1365pandtheefficacyofdocetaxelchemotherapyinmetastaticcastrationresistantprostatecancerpatients
AT furhatishayiti relationshipbetweencirculatingmirna2223pandmirna1365pandtheefficacyofdocetaxelchemotherapyinmetastaticcastrationresistantprostatecancerpatients
AT yueniu relationshipbetweencirculatingmirna2223pandmirna1365pandtheefficacyofdocetaxelchemotherapyinmetastaticcastrationresistantprostatecancerpatients
AT pengchen relationshipbetweencirculatingmirna2223pandmirna1365pandtheefficacyofdocetaxelchemotherapyinmetastaticcastrationresistantprostatecancerpatients